autologous anti-mesothelin TNhYP218 CAR T cells

A preparation of autologous T lymphocytes containing primarily naive and stem cell-like memory (scm) T cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the membrane-proximal region of the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-MSLN TNhYP218 CAR T cells specifically target the membrane-proximal region of MSLN and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Targeting the membrane-proximal region of MSLN may increase the killing of tumor cells and improve T-cell persistence. Naive and scm T cells may exhibit increased persistence and decreased exhaustion.